UNT Health Science Center Campus Gibson D. Lewis Library April 6, 2018 Thank you to our 2018 sponsors & vendors! Biomedical Solutions BioTek Instruments Charles River Envigo Eppendorf Laerdal Medical Merck & Co., Inc. MIDSCI MilliporeSigma Nexcelom Bioscience Office of Research Development PHC Corporation of North America Quest Diagnostics Thermo Fisher Scientific Quest has expanded its services so you can prescribe with confidence A growing crisis demands a growing response According to the US Centers for Disease Control and Prevention, opioids account for more than 60 percent of overdose deaths—nearly 100 each day. In Texas alone, there were 1,107 accidental opioid poisoning deaths in 2016.1 As the industry leader in drug testing, we're happy to offer your practice a broad scope of fast and efficient prescription drug monitoring to help protect your patients. Our PDM service features: • Fast turnaround time • Specimen format flexibility • medMATCH® specimen reporting with easy-to-read-and-interpret results • QuanumTM Electronic Health Record and ePrescribing For more information, ask a Quest rep at the booth or visit QuestPDM.com Quest proudly supports UNTHSC Research Appreciation Day 1. Amid opioid crisis, Texas subsidized drug distributor it's now investigating. The Texas Tribune. October 31, 2017. https://www.texastribune.org/2017/10/31/during-opioid- crisis-texas-subsidized-drug-company-its-now-investigati/. Accessed March 20, 2018. Table of Contents Posters ........................................................................................................................................1 Aging/Alzheimer’s Disease (Abstracts in the 100s) ............................................................................. 1 Biochemistry (Abstracts in the 200s) ................................................................................................. 12 Cancer (Abstracts in the 300s)........................................................................................................... 13 Cardiovascular (Abstracts in the 400s) .............................................................................................. 42 Cell Biology (Abstracts in the 500s) ................................................................................................... 62 Community Medicine (Abstracts in the 600s) ................................................................................... 69 Diabetes (Abstracts in the 700s) ....................................................................................................... 75 Education (Abstracts in the 800s)...................................................................................................... 85 Eye/Vision (Abstracts in the 900s) .................................................................................................... 91 General Medicine (Abstracts in the 1000s) ..................................................................................... 102 General Public Health (Abstracts in the 1100s) ............................................................................... 117 Health Disparities (Abstracts in the 1200s) ..................................................................................... 150 Immunology (Abstracts in the 1300s) ............................................................................................. 154 Integrative Physiology (Abstracts in the 1400s) .............................................................................. 156 Microbiology/Infectious Disease (Abstracts in the 1500s) .............................................................. 167 Molecular Genetics (Abstracts in the 1600s) ................................................................................... 172 Neuroscience (Abstracts in the 1700s) ............................................................................................ 174 Other (Abstracts in the 1800s) ........................................................................................................ 197 Pharmaceutical Sciences (Abstracts in the 1900s) ........................................................................... 230 Pharmacology (Abstracts in the 2000s) ........................................................................................... 234 Physical Medicine/OMM (Abstracts in the 2100s) .......................................................................... 238 Psychology (Abstracts in the 2200s) ................................................................................................ 243 Rehabilitative Sciences (Abstracts in the 2300s) ............................................................................. 251 Structural Anatomy (Abstracts in the 2400s) .................................................................................. 256 Women’s Health (Abstracts in the 2500s) ....................................................................................... 268 Oral Presentations .................................................................................................................. 281 Cancer (Abstracts in the 300s)......................................................................................................... 281 Cardiovascular (Abstracts in the 400s) ............................................................................................ 282 1 Immunology (Abstracts in the 1300s) ............................................................................................. 283 Integrative Physiology (Abstracts in the 1400s) .............................................................................. 285 Neuroscience (Abstracts in the 1700s) ............................................................................................ 286 Women’s Health (Abstracts in the 2500s) ....................................................................................... 289 2 Posters Aging/Alzheimer’s Disease (Abstracts in the 100s) 100 - Poster Classification: GSBS Student Presenter: Ann Abraham Daniel Department: Pharmacology and Neuroscience Authors: Ann Abraham Daniel, MSc (Med Sci); Talisa Silzer, BS; Jie Sun, BS; Nicole Phillips, PhD; Leigh Johnson, PhD; Sid O'Bryant, PhD; Robert Barber, PhD Epigenetic Risk Factors for Mild Cognitive Impairment, Alzheimer’s Disease and Metabolic Dysfunction in Mexican Americans Purpose: Alzheimer’s is the most common form of dementia and the 5th leading cause of death for those over 651. The population of Mexican American elders will grow seven-fold by 20502 with rates of mild cognitive decline (MCI) and Alzheimer’s disease (AD) increasing exponentially1. Mexican Americans are diagnosed with MCI and AD at younger ages than non-Hispanic whites3; 4. In addition, Mexican Americans who are diagnosed with AD are 1) less likely to carry the ApoEε4 genotype3-5., 2) suffer a greater burden of type 2 diabetes3; 6, 3) experience greater metabolic-related cognitive decline 7; 8 and 4) display a proteomic signature of AD that is heavily metabolic in nature4; 9, compared to non-Hispanic whites, whose proteomic signature for AD is dominated by inflammatory proteins. We hypothesized that differentially methylated regions of DNA (DMRs) are associated with age at onset of cognitive decline (MCI/AD) and metabolic dysfunction (metabolic syndrome/type 2 diabetes) in Mexican Americans. Methods: To test this hypothesis, we assayed genomic DNA methylation in samples from 14 female Mexican American participants enrolled in the Health and Aging Brain study in Latino Elders (HABLE). Participants were diagnosed with cognitive decline (n=4), metabolic dysfunction (n=3), both (n=4), or as a control (n=3). We isolated DNA from leukocytes and bisulfite treated the samples before running them on an Illumina MethylationEPIC chip in accordance with manufacturer’s recommendations to assay genomic DNA methylation. Results: Several interesting biological pathways showed significantly different methylation status between groups. When the participants were split on cognitive decline, DNA in the amyloid secretase, EGF receptor signaling, PDGF signaling, gonadotropin-releasing hormone receptor and Wnt signaling pathways were significantly hypermethylated in cases. In comparison, analyses based on metabolic dysfunction showed significant DNA hypomethylation in the beta1 and beta2 adrenergic receptor signaling pathways and hypomethylation of the gonadotropin releasing hormone receptor pathway in cases. Conclusions: The etiology of cognitive decline appears to differ between Mexican Americans and non- Hispanic whites. Future work will resolve how dementia risk differs between these and other ethnic groups. The knowledge gained from these studies will be critical to a better understanding of AD pathophysiology and the development of ethnicity-focused AD treatment options. 1 Acknowledgements: Research reported here was supported by the National Institute On Aging of the National Institutes of Health under Award Number R01AG054073. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The research team also thanks the local Fort Worth community and participants of the Health & Aging Brain Study. Sponsor: R01AG054073 IRB/IACUC#: 2012-083 2 101 – Poster Classification: Faculty / Staff (Not for Competition) Presenter: Tori Conger Department: Pharmacology and Neuroscience Authors: Tori Conger; Melissa Pierce, University of North Texas Health Science Center; James Hall, MD, University of North Texas Health